Clinical Trial Update: A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation and expansion study of ASP4132 in patients with lymphoma and solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• ASP4132

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Lymphoma, Refractory Solid Tumors | Phase 1 | Status: COMPLETED